LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

10.8 -2.96

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.8

Máximo

11.47

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.522 50.102
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+46.72% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.1B
Abertura anterior	13.76
Fecho anterior	10.8

Sentimento de Notícias

By Acuity

10%

90%

7 / 344 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de mai. de 2026, 23:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 de mai. de 2026, 20:53 UTC

Ganhos

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 20:33 UTC

Conversa de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 de mai. de 2026, 20:11 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 19:47 UTC

Ganhos

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 de mai. de 2026, 19:36 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 de mai. de 2026, 19:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 de mai. de 2026, 18:19 UTC

Conversa de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 de mai. de 2026, 18:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 de mai. de 2026, 18:11 UTC

Conversa de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 de mai. de 2026, 18:10 UTC

Conversa de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 de mai. de 2026, 17:55 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 17:55 UTC

Conversa de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 de mai. de 2026, 17:00 UTC

Ganhos

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de mai. de 2026, 16:02 UTC

Conversa de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 de mai. de 2026, 15:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 de mai. de 2026, 15:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 de mai. de 2026, 15:40 UTC

Conversa de Mercado

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Canada's Economy Not Looking All That Bright -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

46.72% parte superior

Previsão para 12 meses

Média 16.8 USD 46.72%

Máximo 20 USD

Mínimo 13.6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Sentimento

By Acuity

7 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.